AGCT1531 for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors - Clinical Trial
What is the Purpose of this Study?
Who Can Participate in the Study?
Female children and adults who:
-Are aged 49 or younger
-Have primary extracranial germ cell tumor
-Have received prior systemic therapy
What is Involved?
If you choose to join this study, you will:
-Be assigned to one of the following groups:
-- Low risk, standard risk 1 or standard risk 2
If you are in:
- Low risk group:
-- Be closely watched for 2 years and less frequently for years 3-5
-- Get blood tests and imaging tests to see if your tumor has came back
- Standard risk 1 and 2 groups:
-- Be put into one of two groups (Like the flip of a coin) to get chemotherapy with bleomycin, etoposide and either cisplatin (standard) or carboplatin (experimental).
-- Get one of the two treatments for either 3 or 4 cycles that last 3 weeks (21 days) each.
-- Have tissue and scans from your tumor tested